U.S. markets open in 27 minutes

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.79+1.31 (+4.95%)
At close: 04:00PM EST
27.80 +0.01 (+0.04%)
Pre-Market: 04:10AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close26.48
Bid24.01 x 1000
Ask33.44 x 1300
Day's Range26.02 - 27.87
52 Week Range23.55 - 36.95
Avg. Volume559,798
Market Cap2.219B
Beta (5Y Monthly)1.58
PE Ratio (TTM)35.72
EPS (TTM)0.78
Earnings DateFeb 21, 2022 - Feb 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MYGN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Myriad Genetics, Inc.
    MYGN: Raising target price to $29.00MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $29.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    20 days agoArgus Research
View more
  • GlobeNewswire

    Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

    SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the company’s strategic transformation and growth plans at the 40th Annual J.P. Morgan Health Care Conference at 2:15 p.m. ET on Jan. 11, 2022. Diaz will discuss the growing role of genetic insights in context with industry trends, new commercial capabilities and products that advance he

  • GlobeNewswire

    Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

    Nationwide search for permanent successor underwaySALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished service. A national search for a permanent CSO is underway. Lanchbury will provide consulting and scientific advisory services for Myriad Genetics through the end of the first

  • Zacks

    Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now

    Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.